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ABSTRACT
SYNERGISTIC EFFECTS OF d-δ-TOCOTRIENOL AND XANTHORRHIZOL
ON MURINE B16 MELANOMA CELLS
by
Darren Chan
Background: Skin cancer has become the most commonly diagnosed cancer in the
United States, of which melanoma is the most lethal form. Conventional chemotherapy
treatments come with a host of side effects. d-δ-Tocotrienol and xanthorrhizol have
shown potential in treatment of cancers. Tocotrienol, an isomer of vitamin E, has
demonstrated apoptotic and cell cycle arrest effects on cancer cells. Xanthorrhizol, a
sesquiterpenoid, has demonstrated anticancer effects through both hormonal and
nonhormonal pathways. It is unknown whether combinations of d-δ-tocotrienol and
xanthorrhizol provide greater growth-suppressive activity than these agents alone.
Methods: The proliferation of murine B16 melanoma cells was measured using MTT
assay with CellTiter 96 Aqueous One Solution (Progmega, Madison WI, USA). Cell
cycle distribution was examined by flow cytometry. Protein expression was detected by
Western blot analysis with chemiluminescent imaging.
Results: Xanthorrhizol inhibited cell proliferation in a dose-response manner. The IC50 of
xanthorrhizol, or the concentration of xanthorrhizol required to suppress the cell
proliferation by 50%, was estimated to be 65 µM. A combination of 16.25 µM
xanthorrhizol and 10 µM d-δ-tocotrienol inhibited cell proliferation to a greater extent
than those by individual compounds (P<0.01), suggesting a synergistic effect. Cell cycle
analysis showed trends towards G1 cell-cycle arrest, though these did not reach statistical

	
  
	
  
significance. Western blot analysis did not demonstrate significant changes in protein
expression across treatment groups in cyclin D1, cyclin-dependent kinase 4, or
procaspase-3.
Conclusion: Xanthorrhizol and d-δ-tocotrienol demonstrate additive and possibly
synergistic effects on the viability of murine B16 melanoma cells. The underlying
mechanisms of action for this finding, including apoptosis and cell cycle, warrant further
investigation.
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CHAPTER I
SYNERGISTIC EFFECTS OF d-δ-TOCOTRIENOL AND XANTHORRHIZOL ON
MURINE B16 MELANOMA CELLS
Introduction
Skin cancer has become the most prevalent type of cancer in the United States
(Gershenwald & Guy, 2016; Guy et al., 2015), within which melanoma is ranked third in
prevalence (CDC, 2017). While melanomas are the least commonly diagnosed skin
cancer, they are the most lethal (CDC, 2017; Gershenwald & Guy, 2016). Melanoma
incidence doubled between 1982 and 2011 (Guy et al., 2015). Due to its rising
prevalence, developing effective treatments has become a priority. While
chemotherapeutic drugs are developed to combat progression of cancers, they are often
derived from natural products: an estimated 40% of medicine is derivative of natural
components (Lahlou, 2013). Natural compounds have demonstrated antimicrobial, antiinflammatory, and anticancer effects (Oon et al., 2015). Two such compounds are
xanthorrhizol, a sesquiterpenoid (Oon et al., 2015), and d-δ-tocotrienol, an isomer of
vitamin E (Eitsuka, Tatewaki, Nishida, Nakagawa, & Miyazawa, 2016). The purpose of
this study is to investigate the effects of these compounds, individually and in
conjunction with each other, on murine B16 melanoma cells.
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CHAPTER II
Literature Review
The epidermis contains roughly 1,500 melanocytes per square millimeter. These
cells serve to produce pigment, dividing when ultraviolet radiation damages the DNA of
keratinocytes. Melanocytes that have undergone abnormal growth patterns, termed
melanocytic neoplasms, can either become benign or malignant lesions (Shain & Bastian,
2016b). Malignant lesions, termed melanomas, demonstrate uninhibited growth of cells
that produce pigment (Weir et al., 2011). Melanomas are divided into two categories
based on sun exposure, chronic sun-damaged skin (CSD) and otherwise (non-CSD).
Melanomas are categorized based on signs of damage due to ultraviolet radiation (Shain
& Bastian, 2016b). Other risk factors for melanoma include family history, predisposition
to freckles, a weakened immune system, and the existence of melanocytic naevi (Weir et
al., 2011). Naevi are cases of melanocyte proliferation that, while benign, contribute to
instances of melanoma due to their sheer number: the average Caucasian will have
approximately 25 naevi exceeding 2 mm in diameter, though this number has a
significant genetic component (Shain & Bastian, 2016a). Prior studies suggest that
manipulation of cell cycle progression could yield control over melanocyte proliferation
(Halaban, 2000).
Xanthorrhizol is found in the essential oil of Curcuma xanthorrhiza Roxb., or
Java turmeric (Noomhorm et al., 2014; Oon et al., 2015). The rhizomes are found
throughout Southeast Asia (Noomhorm et al., 2014; Oon et al., 2015). Once extracted, it
is dissolved in ethanol (Oon et al., 2015). It has historically been used to tighten the
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uterus, especially right after a woman delivers a child to alleviate swelling (Noomhorm et
al., 2014).
Xanthorrhizol has demonstrated anticancer properties through a number of
proposed mechanisms, including antibacterial, anti-inflammatory, and antimicrobial
capabilities (Oon et al., 2015). While the leading cause of skin cancer is ultraviolet
radiation (CDC, 2017), skin cancer is among carcinomas correlated with microbial agents
(Kuper, Adami, & Trichopoulos, 2000). Xanthorrhizol has shown signs of antibacterial
(Hwang, Shim, Baek, & Pyun, 2000; Hwang, Shim, & Pyun, 2000; Rukayadi & Hwang,
2006), anticandidal (Rukayadi & Hwang, 2013; Rukayadi, Yong, & Hwang, 2006), and
antifungal (Rukayadi & Hwang, 2007a, 2007b) capabilities. The proposed mechanism of
xanthorrhizol as an antimicrobial agent suggests it also has anti-inflammatory (Chung et
al., 2007; Devaraj, Esfahani, Ismail, Ramanathan, & Yam, 2010; Lee et al., 2002; Lim et
al., 2005) capacities. These anti-inflammatory properties may contribute to cancer
prevention (Galdiero, Marone, & Mantovani, 2017). Xanthorrhizol also demonstrates
antioxidant (Jantan, Saputri, Qaisar, & Buang, 2012; Lim et al., 2005), antihyperglycemic
(Kim, Kim, Song, & Hwang, 2014), antihypertensive (Campos et al., 2000; PonceMonter, Campos, Aguilar, & Delgado, 1999), antiplatelet (Jantan et al., 2008), estrogenic,
and anti-estrogenic (Anggakusuma, Yanti, Lee, & Hwang, 2009; Noomhorm et al., 2014)
properties. Its estrogenic activity was investigated in relation to breast cancer, in which it
seemed to compound the impact of hormone therapy (Noomhorm et al., 2014).
Tocotrienol and tocopherol are the two vitamin E classes, within which there are
four analogues for each (Aggarwal, Sundaram, Prasad, & Kannappan, 2010). These
isoforms are designated α, β, γ, and δ. These forms are differentiated by the presence of
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three double bonds in the carbon tail in tocotrienols (Aggarwal et al., 2010), which
characterizes tocotrienols as isoprenoids (Aggarwal et al., 2010; Mo, 2013). Both
tocopherols and tocotrienols demonstrate antioxidant activity, and tocotrienols have
anticancer properties (Aggarwal et al., 2010; Mo, 2013). Tocotrienol, including d-δtocotrienol specifically, has been studied with respect to various forms of cancer
(Aggarwal et al., 2010; Fernandes, Guntipalli, & Mo, 2010; He, Mo, Hadisusilo, Qureshi,
& Elson, 1997; Hussein & Mo, 2009; Mo, 2013; Mo & Elson, 1999; Qureshi, Mo,
Packer, & Peterson, 2000). As with xanthorrhizol, anti-inflammatory properties may be at
least partially responsible for the anti-cancer capacities of d-δ-tocotrienol (Mo, 2013).
The effects of tocotrienol on various cancers has been studied in the past, causing cells to
demonstrate cell cycle arrest and apoptosis (Fernandes et al., 2010; He et al., 1997;
Hussein & Mo, 2009; McAnally, Gupta, Sodhani, Bravo, & Mo, 2007; Mo & Elson,
1999). d-δ-Tocotrienol demonstrated inhibition of cell growth through the CDK4 and
procaspase-3 pathways in human melanoma cells (Fernandes et al., 2010).
CDK4 is a member of the cyclin-dependent kinase (CDK) family of genes, which
are responsible for cell proliferation through management of cell-cycle progression and
transcription (Sheppard & McArthur, 2013). There are four stages to the life cycle of a
cell, all of which center around its replication. G1 is the stage before DNA synthesis, S is
the stage during which DNA is synthesized, G2 is the stage before cellular division, and
M is the stage of cellular division (Hamilton & Infante, 2016). CDK4, and its homolog
CDK6, regulate the G1-S transition in mammalian cells (Hamilton & Infante, 2016;
Sheppard & McArthur, 2013). CDK4 phosphorylates the retinoblastoma protein (RB1),
which allows for RNA polymerases I and III to transcribe ribosomal RNA.
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Phosphorylated RB1 results in cells progressing from G1 to S phases and blocks
senescence (Sheppard & McArthur, 2013). The CDK4 pathway has been implicated in a
number of cancers, including melanoma, and is a target for pharmaceutical treatments
(Hamilton & Infante, 2016; Sheppard & McArthur, 2013). Ribociclib inhibits CDK 4 and
6, to be used alongside hormone therapy in breast cancer (Lopez-Tarruella, Jerez,
Marquez-Rodas, Echavarria, & Martin, 2017). Current CDK4/6 inhibitors used to treat
melanoma include LEE01 and palbociclib. They are used alongside mitogen-activated
protrein kinase kinase (MEK) inhibitors binimetinib and trametinib, respectively (Reddy,
Miller, & Tsao, 2017).
Cyclin D1 is a protein closely related to CDK4 in its role, mediating the transition
from the G1 to S phase of cell cycle progression (Alao, 2007; Ramirez, Guitart, Rao, &
Diaz, 2005). In order for DNA to replicate, cyclin D1 must be degraded. It has been
implicated in a number of cancers (Alao, 2007), including melanomas (Reddy et al.,
2017). Cyclin D1 binds to CDK 4 and 6, which stimulates phosphorylation of RB1
(Reddy et al., 2017). While this action stimulates the G1 to S transition (Sheppard &
McArthur, 2013), during which cyclin D1 levels rise steadily, progression beyond the S
phase has been associated with depletion of the protein (Alao, 2007). Conversely,
overexpression of cyclin D1 was associated with increases in cell proliferation (Ramirez
et al., 2005); where cyclin D1 levels usually fall after the S phase transition, cells that
proliferate abnormally have correspondingly irregular cyclin D1 levels.
Caspases are a family of proteins that regulate apoptosis. Among the caspases,
caspase-3 is commonly known for its role in cell death (Porter & Janicke, 1999) .
Caspase enzymes begin as zymogens with low activity. Caspase-3 is the active form of
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procaspase-3 (Peterson et al., 2009). With respect to cancer cell lines, activation of
caspase-3 would ideally bring cell proliferation back down to more normal levels. Due to
its role as a precursor to caspase-3, procaspase-3 has become a target for cancer
treatments seeking to induce apoptosis. Procaspase-3 activating compound 1 (PAC-1)
and its derivatives are being investigated as potential treatments (Peterson et al., 2009).

	
  

	
  

	
  

CHAPTER III
Materials
Murine B16 melanoma cells were received as a gift from the Georgia State
University Department of Biology (Atlanta, GA, USA). Trypsin, Dulbecco’s Modified
Eagle’s Medium (DMEM), fetal bovine serum (FBS) penicillin-streptomycin,
gentamycin, fluconazole, Hank’s Balanced Salt Solution (HBSS), 75 cm2 tissue culture
flasks, 96 well tissue culture plates, CellTiter 96® Aqueous One Solution, and pure
ethanol were purchased from Fisher Scientific LLC (Houston, TX, USA). Xanthorrhizol
and tocotrienol were gifts from Dr. Barrie Tan at American River Nutrition, Inc (Hadley,
MA, USA).
Methods
Cell Growth Assay
Murine B16 melanoma cells were cultured in a 75-cm2 tissue culture flask with DMEM
modified to contain 10% FBS, 1% penicillin-streptomycin, 1% gentamycin, and 0.01%
fluconazole (growth media) until 80-85% confluent. The flask was incubated in a
humidified environment at 37°C, and five percent CO2. The media was then aspirated,
washed with Hank’s Balanced Salt Solution (HBSS), and five mL trypsin was added.
Once the cells were lifted off the flask, about two minutes in the incubator, five mL of
~37°C growth media was added to stop the reaction. The cells were spun down at 2000
RPM for five minutes at 23°C. They were then seeded at 1,200 cell/0.1 mL medium per
well in the 96-well tissue culture plates. Six wells were allotted for each planned
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treatment group. After 24 h, the medium from each well was aspirated and treatment
media was added. Treatments were added to growth media at 0.1% volume. Treatments
for the concentration titration were: an ethanol control and xanthorrhizol 200, 100, 50,
25, 12.5, and 6.25 µM. The IC50 of xanthorrhizol was calculated from these data. 48
hours after treatment (72 h total), the treatment media was aspirated and wells were
washed with warm HBSS. 0.1 mL DMEM without the growth media additions. CellTiter
96® Aqueous One Solution (20 µL) was added to each well, and the plate was incubated
for two hours. The plate was then read by a Synergy HT plate reader and Gen5TM
software from Biotek® Instruments, Inc (Winooski, VT, USA). The cell proliferation
assay for combination of xanthorrhizol and d-δ-tocotrienol was carried out using the
same protocol.

Western Blot
Murine B16 melanoma cells cultured in six-well plates with 9.6-cm2 per well at 3.2 x 105
cells/cm2 were incubated with a growth medium for 24 hours. The growth medium was
comprised of Dulbecco’s Modification of Eagle’s Medium fortified with fetal bovine
serum, penicillin/streptomycin, gentamycin, and fluconazole. After 24 hours, the growth
medium was aspirated and replaced with treatment medium. The treatment medium
consisted of growth medium with 0.1% by volume of the treatments. Treatments were
xanthorrhizol at 16.25 and 32.5 µM, d-δ-tocotrienol at 5 and 10 µM, and combinations of
the two compounds. Treatments were made by diluting stock solutions of each compound
with ethanol. Treatment media was aspirated after 24 hours, and the cells were washed
once with 2 mL warm HBSS. Each well was then treated with 75-150 µL of lysis buffer
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(1% v/v Nonidet P40 Substitute, 1% w/v sodium deoxycholate, 0.05% v/v SDS, 0.81%
NaCl, 0.25% v/v of 1M Tris at pH 6.8, 5% v/v 0.5 M EDTA, 1 mM sodium orthovandate,
50 mM sodium fluoride, 10 mM sodium β-glycerophosphate pentahydrate, 2.5 mM
sodium pyrophosphate, and 1% v/v protease inhibitor cocktail (VWR International,
Suwanee GA, USA)), depending on confluence within the wells, and incubated for 30
minutes on ice. Each treatment was allocated into two 1.5 mL centrifuge tubes and spun
down at 13.3x103 RPM and 4°C for 20 minutes. The supernatant was then collected and
protein estimation was performed (specify the type of protein assay used). 10 µg of
protein after mixing with a loading buffer at 1:3 ratio (v/v) was then loaded into each well
of a 12% SDS gel for Western blot. The loading buffer was made by adding a stock
solution of 270 µL 4x Laemmli buffer to 30 µL 2-mercaptoethanol. Gels were run at 80 V
for room temperature, until the samples cleared the stacking gel. After this, the chamber
was moved to 4°C. The voltage was then increased to 100 V for 20 minutes, and 150 V
afterwards until the loading dye reached the bottom of the gel. The gels were then
removed and soaked, without the stacking gel, in a 1X transfer buffer solution with 1%
SDS. Polyvinylidene difluoride (PVDF) transfer membranes were soaked for 30 seconds
in ethanol and then transferred to 1X transfer buffer. Sponges and filter papers were presoaked in the transfer buffer. Transfer buffer was a 1X Tris glycine solution, in which
20% of the final volume was ethanol. Transfer was accomplished by a Bio-Rad TransBlot Turbo machine (Hercules CA, USA), using 25 V and 1.0 A for 30 minutes. The
membranes were then blocked in a PBS-T solution with 5% nonfat dry milk powder for
30 minutes at room temperature. They were then briefly washed with PBS-T. Primary
antibody solutions were then added, during which membranes were shaken at 4°C
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overnight. Primary antibody for β-actin (Santa Cruz Biotechnology, Dallas TX, USA;
1:1,000 dilution), CDK4 (Santa Cruz Biotechnology, Dallas TX, USA; 1:500 dilution),
procaspase 3 (Sigma-Aldrich Corporation, St. Louis MO, USA; 1:500 dilution), or cyclin
D1 (Cell Signaling Technology, Danvers MA, USA; 1:500 dilution) was added to 4 mL
PBS-T. The membranes were then subjected to three washings with PBS-T for ten, five,
and five minutes respectively. Secondary antibody solutions were then applied at a
1:3000 dilution. The membranes were then washed again with PBS-T three times for ten,
five, and five minutes respectively. Membranes were then stripped using Restore PLUS
Western Blot stripping buffer from Thermo Scientific (Waltham MA, USA). Ten mL of
stripping buffer was added to each membrane for ten minutes, after which they were
washed briefly with PBST and blocked again. The membranes could then be probed
again with different primary antibodies. Membranes were exposed to 1 mL of mixed ECL
(Thermo Scientific, Waltham MA, USA) solution for 30 seconds prior to imaging with an
ImageQuant LAS4000 chemiluminescence imager.

Cell Cycle Distribution
B16 cells were seeded in 25-cm2 flasks at 1x106 cells/flask with 3 mL medium/flask.
After incubating for 24 hours, the medium was changed out for one containing 0.1% (v/v)
of treatment solutions. Treatments included xanthorrhizol at 32.5 and 65 µM, δtocotrienol at 5 and 10 µM, combinations of xanthorrhizol and δ-tocotrienol, and an
ethanol control. The cells were then harvested after an additional 24 hours of treatment.
One sample of 0-hour cells without any treatment was also harvested. Cell collection was
achieved through trypsinization and spun down with centrifugation for cell pellets. These
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were fixed in 1 mL of 70% ethanol at -20°C. These cells were kept at this temperature for
at least 8 hours and up to two weeks before analysis. Samples were washed with 1 mL
phosphate buffered solution (PBS) twice and resuspended in 500 µl PBS containing 0.5
mg RNase A (Roche Diagnostics, Indianapolis IN, USA). They were incubated at 37°C
for 30 min, after which 100 µL of propidium iodide solution was added. The propidium
iodide solution was made by mixing 1 mg of propidium iodide (Sigma-Aldrich, St. Louis
MO, USA) into 1 mL of PBS with 0.1% Triton X-100 (Sigma-Aldrich, St. Louis MO,
USA). The cells were then kept in the dark for 15 minutes before performing analysis.

Statistics
Western Blot bands were quantified using ImageJ (NIH, Bethesda MD, USA). Cell cycle
files (.fcs) were analyzed using FCS Express 6 (De Novo Software, Glendale CA, USA).
Data was analyzed using the Prism software by GraphPad (La Jolla CA, USA) to perform
a one-way analysis of variance (ANOVA) with post-hoc Tukey Test. Significance was
achieved at P<0.05. Values are presented as mean±SEM.

	
  

	
  

	
  

CHAPTER IV
Results
The IC50 value, or concentration required to inhibit cell viability by 50%, of d-δtocotrienol was estimated to be 10 µM from prior studies (He et al., 1997; McAnally et
al., 2007). Xanthorrhizol (0 – 200 µM) demonstrated a dose-dependent inhibition of B16
cell viability. The IC50 value of xanthorrhizol was investigated during this experiment,
and estimated to be 65 µM. Cell viability was inhibited by 8.7 ± 5.2%, 16.1 ± 4.7%, 28.8
± 7.8%, 62 ± 6.3%, and 79.1 ± 6.0% for concentrations of 12.5, 25, 50, 100, and 200 µM,
respectively. Significant differences were seen between control and xanthorrhizol 50 µM
(P<0.01), control and xanthorrhizol 100 µM (P<0.01), control and xanthorrhizol 200 µM
(P<0.01), xanthorrhizol 12.5 µM and 100 µM (P<0.01), 12.5 µM and 200 µM (P<0.01),
25 µM and 100 µM (P<0.01), 25 µM and 200 µM (P<0.01), 50 µM and 100 µM
(P<0.01), and 50 µM and 200 µM (P<0.01) (Figure 1A). Initial tests with a combination
of d-δ-tocotrienol and xanthorrhizol at concentrations of their IC50 values found it too
cytotoxic. Instead, xanthorrhizol at half and a quarter of its IC50 value were tested both
alone and in combination with d-δ-tocotrienol at half and one IC50 value. The results of
cell viability tests are summarized in Figure 1.
Xanthorrhizol at 16.25 and 32.5 µM produced an 11.1 ± 4.6% and 72.5 ± 2.6%
reduction in viable cells, respectively. d-δ-Tocotrienol increased cell viability by 12.0 ±
5.2% and 2.2 ± 4.4% at doses of 5 and 10 µM, respectively, although these were nonsignificant increases. Combinations of xanthorrhizol (16.25 µM) and δ-tocotrienol
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(5 and 10 µM) inhibited cell viability by 18.3 ± 3.3% and 54.7 ± 7.4%, respectively,
exceeding the sum of inhibitions induced by individual agents. Combinations of
xanthorrhizol (32.5 µM) with d-δ-tocotrienol (5 and 10 µM) reduced cell viability by 76.7
± 2.7% and 81.6 ± 2.2%, respectively. The control group was significantly different from
xanthorrhizol 32.5µM (P<0.01), combination of xanthorrhizol (16.25 µM) and d-δtocotrienol (10 µM) (P<0.01), and both combinations with xanthorrhizol 32.5 µM
(P<0.01). Synergy between xanthorrhizol and d-δ-tocotrienol could not be computed by
CompuSyn due to the effect of d-δ-tocotrienol treatments. However, the combination of
16.25 µM of xanthorrhizol and 10 µM d-δ-tocotrienol suggested a synergistic effect.
The effect of the combinations on procaspase-3 was evaluated to show whether
caspase-3 activation is involved in the growth inhibition induced by the compounds. d-δTocotrienol did not appear to induce apoptosis by way of procaspase-3 in B16 melanoma
cells as shown in this preliminary study. A prior study demonstrated that d-δ-tocotrienol
causes a concentration-dependent reduction in procaspase-3 expression in human
melanoma cells (Fernandes et al., 2010). However, there was no trend demonstrated by
any of the treatments used in this study (Figure 2).
Figure 3 shows the effect of the individual and combined treatments on the
percentage of cells in the G1 (Figure 3A), S (Figure 3B) and G2 (Figure 3C) phases of
cell cycle. The 0-hour control had 60.7 ± 1.0 % of cells in G1, which fell slightly to 57.7
± 1.3 % in the 24-hour control (P>0.05). Treatment with xanthorrhizol resulted in 67.0 ±
1.4 % (16.25 µM) and 79.6 ± 2.2 % (32.5 µM) of cells in G1. The 16.25 µM
xanthorrhizol group was significantly different from the higher 32.5 µM group
(P=0.048), suggesting a dose-dependent effect of xanthorrhizol on cell cycle progression.
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d-δ-Tocotrienol treatments yielded 64.4±2.0% (5 µM) and 63.3±5.9% (10 µM) of cells in
G1. Combination treatments resulted in 69.7±1.0% (16.25 µM xanthorrhizol and 5 µM dδ-tocotrienol), 71.9±1.9% (16.25 µM xanthorrhizol and 10 µM d-δ-tocotrienol),
68.5±4.1% (32.5 µM xanthorrhizol and 5 µM d-δ-tocotrienol), and 85.4±2.3% (32.5 µM
xanthorrhizol and 10 µM d-δ-tocotrienol), respectively, of the cells in G1 phase.
Xanthorrhizol at 32.5 µM and the combination of xanthorrhizol (32.5 µM) and d-δtocotrienol (10 µM) increased the G1% (P<0.01), suggesting a G1 arrest. There was also
a trend of non-significant decreases in the S% in these treatment groups. The G1% in
other treatment groups did not reach statistical significance in comparison to that in the
control group. The combination of xanthorrhizol (32.5 µM) and d-δ-tocotrienol (10 µM)
remained significantly different from the other combination treatments, including
xanthorrhizol at 16.25 µM and d-δ-tocotrienol at 5 µM (P<0.01), xanthorrhizol at 16.25
µM and d-δ-tocotrienol at 10 µM (P=0.0232), and xanthorrhizol at 32.5 µM and d-δtocotrienol at 5 µM (P<0.01), suggesting a dose effect in combinations.
S-phase cell cycle data was similarly inconclusive (Figure 3B). The percentages
of cells in S phase were 29.9 ± 1.3 % (0-hour control), 8.9 ± 2.1 % (24-hour control),
29.4 ± 0.6 % (xanthorrhizol 16.25 µM), 12.8 ± 1.5 % (xanthorrhizol 32.5 µM), 26.8 ± 1.1
% (d-δ-tocotrienol 5 µM), 30.7 ± 6.1 % (d-δ-tocotrienol 10 µM), 22.2 ± 1.1 %
(xanthorrhizol 16.25 µM and d-δ-tocotrienol 5 µM), 15.7 ± 3.0 % (xanthorrhizol 16.25
µM and d-δ-tocotrienol 10 µM), 18.3 ± 1.9 % (xanthorrhizol 32.5 µM and d-δ-tocotrienol
5 µM), and 8.7 ± 2.1 % (xanthorrhizol 32.5 µM and d-δ-tocotrienol 10 µM). The 0-hour
control was different from the 24-h control (P<0.01), suggesting that cells are
transitioning through the cell cycle in the time period. The S% in the combination group
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consisting of 16.25 µM xanthorrhizol and 10 µM d-δ-tocotrienol was significantly lower
than those in groups with either compounds alone (P<0.01), suggesting a cumulative
	
  

effect. Similar differences were found in the combination group consisting of 32.5 µM
xanthorrhizol and 10 µM d-δ-tocotrienol.
As with the cell cycle data, western blot analysis of associated proteins were
inconclusive. CDK4 and cyclin D1 demonstrated no changes suggestive of cell cycle
alteration (Figure 4).

	
  

	
  

	
  

CHAPTER V
Discussion
This study investigated the anti-proliferative effects of d-δ-tocotrienol (IC50=10
µM) (He et al., 1997; McAnally et al., 2007) and xanthorrhizol, alone and in
combination, on murine B16 melanoma cells. The cell viability data shown here suggest
that there may be a synergistic effect between xanthorrhizol and d-δ-tocotrienol at the
lower xanthorrhizol dose of 16.25 µM. However, the 32.5 µM dose of xanthorrhizol
inhibited cell viability so drastically that the addition of d-δ-tocotrienol did not produce a
compounded effect. Cell viability at both 24 h and 48 h were so low when both
compounds were used at their IC50 values in the combination that the concentrations
necessitated reduction. Additionally, the increased cell proliferation, although nonsignificant from that of the control cells, at both doses (5 µM and 10 µM) of d-δtocotrienol prohibited computation of synergistic effects using the CompuSyn program as
initially planned.
Cell cycle analysis provided inconclusive results. The data shown in this study did
not confirm cell cycle arrest at the G1 phase as shown in prior studies with murine B16
cells (Fernandes et al., 2010) and other cell lines (Hussein & Mo, 2009; Mo & Elson,
1999). While this study suggests a trend towards G1 cell-cycle arrest, which would be in
line with prior studies, this trend did not achieve statistical significance. This could have
been due to several factors. Analysis showed a significant proportion of aneuploid cells in
some groups, and only diploid cell data was used when considering the proportion of
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cells in each phase. There may be an insufficient number of viable cells in the treatment
groups as a result of either treatment concentrations or duration. Future studies could alter
the number of events recorded by the flow cytometer, either in general or between G1
and S phases, or decrease the treatment time.
Western blot analysis was also inconclusive with respect to the proteins
investigated. Prior studies demonstrated effects of d-δ-tocotrienol on cyclin D1, CDK4,
and procaspase-3 (Fernandes et al., 2010; Ji et al., 2012). Some studies showing the effect
of tocotrienols on procaspase-3 and CDK4 had the same cell line as in this study
(Fernandes et al., 2010), while others showing the effect on cyclin D1 used lung cancer
cells (Ji et al., 2012). Several factors could have contributed to the discrepancies between
this and prior studies. First, doses of the compounds could be adjusted. In this study,
there were very few cells after 24 hours of treatment with the higher doses of
xanthorrhizol and combinations due to the inhibition of cell proliferation. Second, a
shorter treatment period may detect the changes that occurred earlier than the measured
time point. A prior study established that cyclin D1 and CDK4 expression could be
altered in as little as 12 hours (Katuru et al., 2011). Third, only monolayers of cells
remaining attached to the culture plate were harvested for cell cycle and protein analyses.
However, many cells detached as floaters due to the effect of the higher dose of
xanthorrhizol, and these cells were not part of the analysis. The sourcing of primary
antibodies also proved slightly problematic. All three primary antibodies were purchased
from separate companies, and provided differing qualities in imaging. Both the CDK4
and procaspase-3 primary antibody products yielded images with much more background
and nonspecific protein binding when compared to that of cyclin D1. Future studies could
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investigate the effects of reduced treatment time, thus diminishing the cytotoxic effects of
the treatments and increasing the possibility of observing altered protein expressions in
cyclin D1, CDK4, and procaspase-3 at a different time point.
While the majority of results in this study were inconclusive, there were some
positive yields. The IC50 value of xanthorrhizol for murine B16 melanoma cells was
calculated to be approximately 65 µM. The IC50 value for d-δ-tocotrienol in the same cell
line has been established in prior studies (He et al., 1997; McAnally, Jung, & Mo, 2003).
Differences in compound preparation and cell culture conditions may have contributed to
the discrepancies between this (Figure 1B) and prior studies. The inhibition of cell
viability induced by the xanthorrhizol and d-δ-tocotrienol may have impacted the cell
cycle and especially Western blot results. There were very few cells adhering to flasks
and plates after the 24-hour treatment time. Since cyclin D1 and CDK4 expression can be
affected in as little as 12 hours (Katuru et al., 2011), a shorter treatment time could be an
area for future studies with respect to harvesting cells for cell cycle and Western blot
analyses.
Furthermore, a number of alternative proteins exist to regulate both cell cycle and
apoptosis. Tocotrienols in general have been implicated in the regulation of a number of
cell cycle and apoptosis modulators (Aggarwal et al., 2010). This study investigated
expression of proteins present in whole-cell lysates, but there are a number of proteins
that could be further evaluated in fractionated cells. Ras is a gene that encodes for
proteins found in the membrane fraction of cells when activated (Adjei, 2001) and whose
expression has been shown to be affected by d-δ-tocotrienol (Fernandes et al., 2010). Ras
protein acts as a gatekeeper to the expression of several other proteins governing cell
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cycle regulation, proliferation, and differentiation (Adjei, 2001). Investigation of Ras
could also open a window to the mevalonate pathway, as it is one of many protein types
that requires prenylation for activity. Prenylation involves covalent addition of farnesyl or
geranylgeranyl to the protein of interest (Adjei, 2001). The farnesyl and geranylgeranyl
groups are derived from mevalonate that is in turn converted from 3-hydroxy-3methylglutaryl (HMG)-CoA by HMG-CoA reductase (HMGCR) (Buhaescu & Izzedine,
2007). d-δ-Tocotrienol has already been suggested to act upon the mevalonate pathway in
cancer cells (Eitsuka et al., 2016; Fernandes et al., 2010; Hussein & Mo, 2009; McAnally
et al., 2007) through down-regulation of HMGCR. While HMGCR is the main regulator
of the mevalonate pathway, there are a number of other points of control (Buhaescu &
Izzedine, 2007). These other proteins may warrant investigation as well, since
xanthorrhizol clearly demonstrated its ability to inhibit cell viability in addition to the
effects induced by d-δ-tocotrienol.
In summary, xanthorrhizol and d-δ-tocotrienol demonstrated combinational effect
on the viability of B16 melanoma cells with used in doses lower than their IC50 values.
Their effects on cell cycle arrest and apoptosis remain inconclusive. However, the
combination may hold potential in the prevention or treatment of melanoma pending
further studies on their mechanisms of action.
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Figure	
  1.	
  (A)	
  The	
  dose-‐dependent	
  effect	
  of	
  xanthorrhizol	
  on	
  murine	
  B16	
  melanoma	
  cell	
  viability.	
  	
  IC50	
  value	
  for	
  
xanthorrhizol	
  was	
  calculated	
  using	
  Prism	
  7.	
  (B)	
  Effect	
  of	
  combinations	
  of	
  xanthorrhizol	
  and	
  d-‐δ-‐tocotrienol	
  on	
  cell	
  
viability.	
  The	
  combination	
  of	
  xanthorrhizol	
  at	
  16.25	
  μM	
  and	
  10	
  μM	
  d-‐δ-‐tocotrienol	
  reduced	
  cell	
  viability	
  to	
  a	
  greater	
  
extent	
  than	
  those	
  induced	
  by	
  individual	
  agents,	
  suggesting	
  synergy.	
  Combinations	
  of	
  d-‐δ-‐tocotrienol	
  and	
  32.5	
  μM	
  
xanthorrhizol	
  did	
  not	
  produce	
  synergy.	
  Values	
  are	
  mean	
  ±	
  SEM,	
  n	
  =	
  18.	
  Significance	
  levels:	
  *	
  =	
  P<0.05,	
  **	
  =	
  P<0.01,	
  ***	
  
=	
  P<0.001,	
  ****	
  =	
  P<0.0001.	
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Figure	
  2.	
  (A)	
  Representative	
  blots	
  showing	
  the	
  impact	
  of	
  xanthorrhizol	
  (16.25	
  μM	
  and	
  32.5	
  
μM)	
  and	
  d-‐δ-‐tocotrienol	
  (5	
  μM	
  and	
  10	
  μM)	
  on	
  procaspase-‐3	
  expression.	
  (B)	
  Quantification	
  of	
  
procaspase-‐3	
  bands	
  shown	
  in	
  (A).	
  The	
  intensity	
  of	
  procaspase-‐3	
  band	
  was	
  normalized	
  by	
  that	
  
of	
  β-‐actin.	
  X	
  is	
  an	
  abbreviation	
  for	
  xanthorrhizol,	
  while	
  T	
  is	
  an	
  abbreviation	
  for	
  d-‐δ-‐tocotrienol.	
  
Dosages	
  are	
  included	
  without	
  the	
  μM	
  unit.	
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Figure	
  3.	
  The	
  effect	
  of	
  xanthorrhizol	
  and	
  d-‐δ-‐tocotrienol,	
  
individually	
  and	
  in	
  combination,	
  on	
  the	
  
	
   of	
  B16	
  cells	
  in	
  the	
  G1	
  (A),	
  S	
  (B),	
  and	
  G2	
  (C)	
  phases.	
  Significance	
  levels:	
  	
  	
  	
  *	
  =	
  P<0.05,	
  **	
  =	
  
distribution	
  
P<0.01,	
  ***	
  =	
  P<0.001,	
  ****	
  =	
  P<0.0001.	
  	
  

	
  

	
  

23	
  

A	
  

	
  
	
   C	
  
	
  

	
  B	
  
	
  

	
  

	
  
Figure	
  4.	
  (A)	
  Representative	
  blots	
  showing	
  the	
  impact	
  of	
  xanthorrhizol	
  (16.25	
  μM	
  and	
  32.5	
  μM)	
  and	
  d-‐δ-‐
tocotrienol	
  (5	
  μM	
  and	
  10	
  μM)	
  on	
  CDK4	
  and	
  cyclin	
  D1	
  expression.	
  Quantification	
  of	
  (B)	
  CDK4	
  and	
  (C)	
  
Cyclin	
  D1	
  Western	
  blot	
  bands.	
  Xan	
  is	
  an	
  abbreviation	
  for	
  xanthorrhizol,	
  while	
  Toco	
  is	
  an	
  abbreviation	
  for	
  
d-‐δ-‐tocotrienol.	
  Dosages	
  are	
  included	
  without	
  the	
  μM	
  unit.	
  Values	
  are	
  mean	
  ±	
  SEM,	
  n	
  =	
  18.	
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